Pulike Biological Engineering

Pulike Biological Engineering EBIT per Share

The EBIT per Share of Pulike Biological Engineering (603566.SS) as of Oct 18, 2026 is 0.56 CNY. In the previous year, EBIT per Share was 0.28 CNY — a change of 97.34% (higher).

EBIT per Share

0.56CNY

YoY

97.34%

Last updated:

EBIT per Share of Pulike Biological Engineering is 2025 0.56 CNY. EBIT per Share of Pulike Biological Engineering was 2024 0.28 CNY. It decreases by 97.34% higher compared to the previous year.

The Pulike Biological Engineering EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
0.94 CNY
Jan 1, 2022
0.50 CNY
Jan 1, 2023
0.53 CNY
Jan 1, 2024
0.28 CNY
Jan 1, 2025
0.56 CNY
Jan 1, 2026 (e)
0.52 CNY
Jan 1, 2027 (e)
0.57 CNY
Jan 1, 2028 (e)
0.78 CNY
The Pulike Biological Engineering EBIT per Share history
YEAREBIT per ShareYoY
est0.78CNY+37.56%
est0.57CNY+8.49%
est0.52CNY-6.13%
0.56CNY+97.34%
0.28CNY-46.95%
0.53CNY+6.25%
0.50CNY-46.48%
0.94CNY+38.80%
0.67CNY+110.97%
0.32CNY-23.84%
0.42CNY+21.55%
0.35CNY-40.01%
0.58CNY+26.60%
0.45CNY-30.38%
0.65CNY+31.82%
0.50CNY+16.45%
0.43CNY+9.67%
0.39CNY+42.40%
0.27CNY-14.79%
0.32CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pulike Biological Engineering Stock analysis

What does Pulike Biological Engineering do? Pulike Biological Engineering Inc, listed on the Shanghai Stock Exchange with ticker 603566.SS and ISIN CNE1000025N0, is a pharmaceutical company based in Luoyang, China. The company went public on May 18, 2015. It employs 1,718 people and operates within the healthcare sector, specifically in the pharmaceuticals industry. Pulike Biological Engineering focuses on the research, development, manufacturing, and sale of biological products for animals, chemical drugs, and Chinese veterinary drugs. The company's veterinary biological products include vaccines and antibodies, which are used for the prevention and control of infectious diseases in poultry and livestock. Its veterinary chemical medicines are primarily used for treating epidemic diseases affecting poultry and livestock. The company is headquartered in Luoyang, Henan, and its website is http://www.pulike.com.cn/. Pulike Biological Engineering Inc is engaged in the research, development, production, and distribution of veterinary biological products and chemical medicines. The firm's product portfolio targets the prevention and treatment of diseases in animals, with a focus on poultry and livestock health management. Pulike Biological Engineering is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulike Biological Engineering stock

EBIT per Share of Pulike Biological Engineering is 0.56 CNY in 2025.

EBIT per Share of Pulike Biological Engineering changed from 0.28 CNY to 0.56 CNY, representing a 97.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Pulike Biological Engineering since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Pulike Biological Engineering

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Pulike Biological Engineering